Glooko and Hedia announced today that launched their interoperable solution for advanced bolus insulin dosing support.
The solution combines connected care, remote patient monitoring and digital therapeutic technologies. It aims to enhance access for people with type 1 and type 2 diabetes requiring advanced bolus insulin dosing support. The companies kicked off their launch in the UK and expect future rollouts in European countries.
With the Glooko platform, patients can share diabetes data with healthcare providers. That includes blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. Integrating the Hedia Diabetes Assistant adds seamless, personalized support for calculating insulin doses. This simplifies diabetes management and supports more consistent blood glucose levels.
The combination personalizes care and reduces the burden of manually calculating required doses. When used with connected insulin pens, this combination brings enhanced visibility for providers managing patients on multiple daily injection therapy. Glooko and Hedia first struck an agreement to integrate technologies in April 2023.
“We are very pleased to bring this algorithm-driven, personalised innovation to diabetes patients and their healthcare teams through our partnership with Hedia.” said Mike Alvarez, Glooko CEO. “With extensive clinical data supporting Hedia’s efficacy, this solution provides an alternative for those unable to access insulin pumps, ensuring more effective management of MDI therapy. This partnership reflects Glooko’s commitment to advancing digital health tools that optimise diabetes care and help stabilise blood glucose levels through personalised, connected care.”
